Serum IL-4 As a marker of immunological response to sublingual immunotherapy

Giorgio Ciprandi, M. De Amici, G. Murdaca, B. M. Colombo, S. Quaglini, G. Marseglia, M. Di Gioacchino

Research output: Contribution to journalArticlepeer-review


Allergic rhinitis (AR) is characterized by a Th2 polarized immune response. Specific Immunotherapy modifies this bias restoring a physiologic Th1 profile. Sublingual immunotherapy (SLIT) iS widely prescribed, but there is no early, simple marker of response. This study was undertaken in order to determine whether serum IL-4 might be a possible marker of SLIT immunological response in order to quickly and easily detect responder patients. Thirty-nine AR patients with a pollen allergy assumed pre- seasonal SLIT for 3 months. VAS for symptoms and medication efficacy were evaluated. Serum IL-4 was assessed before and 3 and 6 months after SLIT initiation. Eighty-two percent of patients (32/ 39) showed a clinical response to SLIT. Serum IL-4 significantly decreased at 6 months post-therapy in responders, whereas it increased in non-responders. In conclusion, these results may be considered clinically relevant proof that SLIT treatment induces a quick reduction in Th2 polarization. Serum IL-4 appears to be an early marker of immunological response to SLIT.

Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalJournal of Biological Regulators and Homeostatic Agents
Issue number2
Publication statusPublished - Apr 2008


  • Response marker
  • Serum il-4
  • Sublingual immunotherapy
  • Th2 cells

ASJC Scopus subject areas

  • Immunology
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Physiology (medical)
  • Medicine (miscellaneous)
  • Physiology
  • Agricultural and Biological Sciences(all)


Dive into the research topics of 'Serum IL-4 As a marker of immunological response to sublingual immunotherapy'. Together they form a unique fingerprint.

Cite this